Updated Version 3 - According to the Financial Times, McKesson and CD&R are close to reaching a deal worth more than $5 billion to acquire Option Care.
路透社2026/10/05 21:18In the fifth paragraph, a quote from analyst Sahil Pandey was added. Reuters, October 5 - According to the Financial Times, citing informed sources, pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice are about to reach an acquisition agreement to purchase infusion service provider Option Care Health, with the deal valued (including debt) at over 5 billions USD. After the report was published, Option Care's share price rose by 21% in after-hours trading. The report stated that the deal could be announced as early as Tuesday, but negotiations could still fall through. This potential acquisition would be McKesson’s latest move in expanding its healthcare services portfolio. In August this year, the company agreed to acquire Precision Medicine Group for about 2.25 billions USD (link), as part of its effort over the years to strengthen high-growth business sectors. Leerink Partners analyst Michael Cherny said the “strategic logic” of the deal makes sense, as it would expand McKesson’s business from physician offices to care settings in the home and alternative sites. Option Care provides infusion services that allow patients to receive intravenous treatments at home or other outpatient settings, eliminating the need to go to the hospital. McKesson has previously been restructuring its business portfolio by divesting non-core assets and investing in fields such as oncology and specialty care (link). Driven by the growth of its specialty distribution business and contributions from acquisitions, revenue for its oncology and multi-specialty business segment grew by 33% in the latest fiscal quarter. McKesson declined to comment, while CD&R and Option Care did not immediately respond to Reuters’ requests for comment regarding the report. (For non-English speakers' convenience, Reuters offers automated machine translations of its reports in several languages. As there may be mistakes in the automated translations or some context may not be included, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters bears no responsibility for any damages or losses caused by the use of automated translation functions.)
Added analyst's quote in paragraph 5
Sahil Pandey
Reuters, October 5 - According to the Financial Times on Monday, citing sources familiar with the matter, pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice are close to reaching an agreement to acquire infusion services provider Option Care Health in a deal valued (including debt) at over $5 billion.
After the report was published, Option Care's share price rose 21% in after-hours trading.
The report also stated that the deal could be announced as early as Tuesday, but negotiations could still fall through.
This potential acquisition would be the latest move by McKesson as it seeks to expand its healthcare services portfolio. In August this year, the company agreed to acquire Precision Medicine Group for about $2.25 billion (link), as part of its multi-year effort to strengthen high-growth businesses.
Leerink Partners analyst Michael Cherny said the “strategic logic” behind the deal is sound, as it would expand McKesson’s reach from physicians’ offices to care settings in the home and alternative locations.
Option Care’s infusion services enable patients to receive intravenous treatments at home or in other outpatient settings without having to go to the hospital.
McKesson has previously been (link) restructuring its business portfolio by divesting non-core assets and investing in areas such as oncology and specialty care.
Thanks to growth in the specialty distribution business and contributions from acquisitions, revenue from its oncology and multi-specialty business segment grew 33% in the latest quarter.
McKesson declined to comment, while CD&R and Option Care did not respond immediately to Reuters’ request for comment on the report.
(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, and it is provided solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold prices continue to fall as HSBC casts doubts and predicts further decline
Jeff Kilburg Backs 2 Tech Picks Even When They Trade Above Analyst Targets
Citigroup: Japanese bond yields may have reached their peak, clearer fiscal outlook will enhance investment appeal
Citigroup strategists believe that Japanese government bond yields may be approaching their peak, and they expect financial institutions to increase investments in Japanese bonds as the country's fiscal policy outlook becomes clearer.
